UR-13870 is a p38 mitogen-activated protein kinase (MAPK) inhibitor potentially for the treatment of autoimmune disease and neuropathic pain. UR-13870 treatment significantly reduced OX-42, metabotropic glutamate type 5 receptor (mGluR5), and NMDA (N-methyl-d-aspartate) 2B subunit receptor (NR2B) expression in the anterior cingulate cortex after spinal cord injury. UR-13870 treatment significantly decreased hindlimb hyperreflexia to both mechanical and cold stimuli after spared nerve injury without loss of general motor function, in addition to a reduction in pain-related anxiety behavior at day 21 after spared nerve injury, accompanied by normalization of OX-42 immunoreactivity within the ipsilateral lumbar dorsal horn.
MedKoo Cat#: 527904
Name: UR-13870
CAS#: 755753-89-0
Chemical Formula: C24H16F2N4
Exact Mass: 398.1343
Molecular Weight: 398.42
Elemental Analysis: C, 72.35; H, 4.05; F, 9.54; N, 14.06
The following data is based on the product molecular weight 398.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
